Amphivena Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amphivena Therapeutics, Inc. - overview
Established
2012
Location
San Francisco, CA, US
Primary Industry
Pharmaceuticals
About
Amphivena Therapeutics, Inc. is a biotechnology company that focuses on developing innovative therapies for treating cancer and other diseases by harnessing the power of the immune system. Founded in 2012 in San Francisco, US, Amphivena Therapeutics, Inc. specializes in creating immunotherapies to combat cancer.
The company's strategic focus has remained consistent since its inception. The CEO, Curtis Ruegg, leads the organization, which has raised a total of USD 23. 30 mn in its Series C funding round as of September 24, 2019, with prominent investors including NanoDimension and Qiming Venture Partners. The total amount raised by the company stands at USD 23.
30 mn, with a current valuation of USD 277. 24 mn. Amphivena Therapeutics develops groundbreaking immunotherapeutic products aimed at treating cancer. Their flagship therapeutic candidates are designed to engage the immune system to target and eliminate cancer cells effectively, enhancing treatment outcomes for patients.
Amphivena Therapeutics does not currently generate revenue from product sales, as the company is in the development phase of its therapeutic candidates. Funding obtained from investors supports research and development activities to advance their product pipeline. Following their Series C funding round in September 2019, which raised USD 62 mn, Amphivena Therapeutics, Inc. plans to utilize these funds to further advance its lead therapeutic candidate.
The company is focused on progressing its clinical trials and exploring potential new products, with an emphasis on expanding its market presence in the oncology field.
Current Investors
Industrial Investors, Qiming Venture Partners, AJU IB Investment
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.amphivena.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Amphivena Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.